Home
Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. Market Share Analysis for May 2026

Guided by Science

Health > Biotechnology and Pharmaceuticals

Domainspyre.com

Year Founded2013

Employees51 - 200

Annual Revenue< $1M

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. (including company regionals)

spyre.com

See more website traffic and engagement information

Total visits to Spyre Therapeutics, Inc.'s top domains

Understand Spyre Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

spyre.com9.3K

See more with Sales Intelligence

Avg. visit duration in Spyre Therapeutics, Inc.'s top domains

Analyze Spyre Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

spyre.com00:00:14

See more with Sales Intelligence

Avg. pageviews on Spyre Therapeutics, Inc.'s top domains

See how Spyre Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

spyre.com1.76

See more with Sales Intelligence

Spyre Therapeutics, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

apogeetherapeutics.comCompany NameApogee TherapeuticsEmployees201 - 500HQUnited States, Massachusetts, WalthamAnnual revenue--Total visits27.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Spyre Therapeutics, Inc.

These are the website technologies, by industry, used by Spyre Therapeutics, Inc. top domains

Conversion & Analytics (3)

Google Analytics

Email Services (2)

G Suite

Mobile (2)

Meta Viewport

Audio Video Media (1)

Vimeo

More Technologies

5

See all

News & Signals from Spyre Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSpyre Infostructure Inc. partnered with Paragon Therapeutics, Inc. on Jun 3rd '26.Spyre Therapeutics (SYRE) stock is back in focus after the company amended its SPY003 license with Paragon Therapeutics, expanding rights beyond inflammatory bowel disease to broader uses while keeping clear dosing limits for non IBD indications.

NewsSpyre Infostructure Inc. is developing long-acting antibodies targeting TL1A and IL-23.Beyond SPY001, Spyre is developing long-acting antibodies targeting TL1A and IL-23.

NewsBruno left Spyre Infostructure Inc. on Feb 1st '26.Prior to joining Immuneering in February 2026, Ms. Bruno held Quality leadership roles at Entasis Therapeutics, Spyre Therapeutics, and Geron Corporation.